Business Wire

ReNAgade Therapeutics to Present Preclinical Data Demonstrating Potent Extra-Hepatic Delivery of mRNA Using Proprietary Lipid Nanoparticles at 11 th International mRNA Health Conference


ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced it will present preclinical data demonstrating novel and proprietary lipid nanoparticle (LNP)-based delivery of mRNA to extra-hepatic tissue in a plenary session at the 11th International mRNA Health Conference, being held October 31 to November 2, 2023 in Berlin, Germany.

“These are encouraging data highlighting how ReNAgade’s industry-leading delivery platform can help us target a broader range of therapeutic areas beyond the liver and position us to overcome the limitations of RNA medicines,” said Pete Smith, Ph.D., Chief Scientific Officer of ReNAgade. “Delivery to extra-hepatic tissue is foundational to our approach, and these data help validate how our diverse LNP library can complement our multi-modal RNA platform to create a robust therapeutic pipeline. We look forward to building impactful RNA medicines using novel technologies to target indications with unmet medical needs that were previously not tractable due to poor delivery.”

Key Highlights from the Presentation:

  • Delivery of proprietary LNPs encasing cre-recombinase mRNA led to in vivo editing in both short- and long-term hematopoietic stem cells (HSCs), as well as multipotent progenitor cells (MPP) after a single intravenous administration in a murine reporter system. Reporter-positive (cre+) colonies were observed in bone marrow colony forming assays at 24 hours.
  • Delivery of reporter mRNA via a proprietary LNP resulted in mRNA expression in CD34+ hematopoietic stem and progenitor cells (HSPC) in non-human primate (NHP) and humanized murine models 24 hours after a single intravenous administration.
  • Proprietary LNP delivery to natural killer (NK) cells was also identified via a high-throughput, functional barcoding screening in NHP models.
  • Taken together, potent delivery of ReNAgade’s proprietary LNPs was observed in natural killer cells and several subsets of HSCs over multiple animal models (including NHP and humanized murine models), demonstrating robust LNP delivery of mRNA cargo to extra-hepatic tissue.

Details of the Presentation:

TITLE: “Novel LNP-Based Delivery of mRNA to Extra-Hepatic Tissues in NHPs”

PRESENTER: Muthusamy Jayaraman, Ph.D., Senior VP Delivery Chemistry, ReNAgade Therapeutics

DATE AND TIME: Wednesday, November 1, 2023 at 3:18PM CET (10:18AM ET)

About ReNAgade Therapeutics

ReNAgade exists to unlock the potential for RNA medicines to treat disease anywhere in the body. We combine our novel RNA delivery platforms with a comprehensive RNA platform allowing for an all-RNA system for coding, editing, and gene insertion to develop new medicines.

To accelerate the future of medicine, we bring together a team with deep RNA and delivery expertise to develop paradigm-shifting RNA medicines.

ReNAgade Therapeutics—RNA Without Limits

For more information about the company, its technologies, and its leadership, visit

To view this piece of content from, please give your consent at the top of this page.

Contact information

Investor Relations:
Emily Brabbit, Argot Partners
(212) 600-1902

Media Relations:
Sarah Sutton, Argot Partners
(212) 600-1902

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

V-Nova completes the acquisition of Parallaxter Srl, the company behind the PresenZ XR technology29.11.2023 10:00:00 CET | Press release

V-Nova, a leading provider of data compression solutions, announces the full acquisition of Parallaxter Srl, completing its prior investments in the company and incorporating it into the V-Nova group. Parallaxter are the XR experts behind the PresenZ technology and this acquisition will greatly expand V-Nova’s portfolio of IP and technologies in VR/XR and gaming, as well as further strengthen its position in the data and video compression industry. V-Nova PresenZ, a Lumiere Award winning format that combines Parallaxter's PresenZ technology and V-Nova's point-cloud compression, is set to revolutionize storytelling in VR. It offers users cinematic photorealism and 6DoF for real-time navigation in pre-rendered scenes, breaking free from static viewpoints and ensuring full immersiveness. V-Nova PresenZ is distributed at scale also to stand-alone XR devices thanks to MPEG-5 LCEVC enhanced pixel streaming. The format dovetails with standard Computer Graphics and Special FX production workfl

PUMA RE:SUEDE Pilot Project Turns Experimental Sneakers Into Compost29.11.2023 09:29:00 CET | Press release

Sports company PUMA showed that it can successfully turn an experimental version of its classic SUEDE sneaker into compost under certain tailor-made industrial conditions, as it announced the results of its two-year-long RE:SUEDE experiment. This press release features multimedia. View the full release here: Sports company PUMA showed that it can successfully turn an experimental version of its classic SUEDE sneaker into compost under certain tailor-made industrial conditions, as it announced the results of its two year-long RE:SUEDE experiment. (Photo: Business Wire) In 2021, PUMA created 500 pairs of the experimental RE:SUEDE, using Zeology tanned suede, a TPE outsole and hemp fibres. The RE:SUEDEs were worn for half a year by volunteers in Germany to test the comfort and durability of the shoes before PUMA sent them to a specially equipped industrial composting area operated by its partner Ortessa Group in the Netherlands. A

Matmut Selects Earnix to Deliver Comprehensive Modeling, Pricing, and Rating Engine29.11.2023 09:00:00 CET | Press release

Earnix, the global provider of AI-based SaaS solutions for insurers and banks, today announced that Matmut, a major mutual insurer in France, has chosen, and is now working with, Earnix as its partner. Matmut is one of France's leading property and casualty insurers, offering a range of personal and commercial insurance products. Earnix solutions address Matmut's business and IT needs by integrating easily into its tech stack, enabling rapid pricing adjustments. With Earnix, Matmut can seamlessly integrate machine learning models as part of its pricing strategy. This enables Matmut to not only build, test, and deploy rates into the market with ease, but also benefit from automation, governance, and auditability. Emeric Bellanger, Technical Director of Claims and Pricing at Matmut said, “This partnership empowers our pricing team to provide top leaders with recommended pricing changes based on simulation and the ability to implement these changes more easily." Earnix solutions enable ne

Global Healthcare Leaders Advance Sector Decarbonisation Ahead of COP2829.11.2023 08:00:00 CET | Press release

To accelerate the transition to net zero health systems, global healthcare leaders from the Sustainable Markets Initiative Health Systems Task Force are in advanced discussions with energy providers in China and India to scale renewable power across their supply chains. This is the first time that companies from across the global healthcare sector – including AstraZeneca, GSK, Novo Nordisk, Roche – have come together to pioneer such initiatives in these countries. China and India are key markets for pharmaceuticals manufacturing, estimated to account for up to 50% of materials for medicines.i This press release features multimedia. View the full release here: Air pollution over Shanghai illustrating the climate health crisis. (Photo: Business Wire) In China, the power agreements would unlock renewable energy in Jiangsu, Guangdong, Shanghai and Beijing. The agreements are set to bring around 70 megawatts (MW) of renewable power a

Capcom Reveals Dragon’s Dogma 2 Scheduled to Launch March 22, 2024!29.11.2023 02:00:00 CET | Press release

Capcom Co., Ltd. (TOKYO:9697) today announced that Dragon’s Dogma 2, the latest game in the Dragon’s Dogma series, is scheduled to be released on March 22, 2024. With the launch of Dragon’s Dogma 2, Capcom closes out a stellar year of major title releases for its 2023 fiscal year. This press release features multimedia. View the full release here: Dragon's Dogma 2 is a single player, narrative driven action-RPG and the latest title in the Dragon’s Dogma series. The game features intricately crafted, gorgeous visuals powered by Capcom’s proprietary RE ENGINE that elevate its unique gameplay experience to provide a truly immersive fantasy world sure to delight both newcomers as well as long-time fans of the series. (Graphic: Business Wire) Dragon’s Dogma 2 is the latest title in the series, and the first mainline entry since the original Dragon’s Dogma was released in 2012. The game is being developed on Capcom’s proprietary RE EN